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Molecular deletion of transglutaminase 2 (TG2) has been shown to improve function and survival in a host of neurological conditions
including stroke, Huntington’s disease, and Parkinson’s disease. However, unifying schemes by which these cross-linking or polyami-
nating enzymes participate broadly in neuronal death have yet to be presented. Unexpectedly, we found that in addition to TG2, TG1 gene
expression level is significantly induced following stroke in vivo or due to oxidative stress in vitro. Forced expression of TG1 or TG2
proteins is sufficient to induceneuronal death inRattusnorvegicus cortical neurons in vitro. Accordingly,moleculardeletionofTG2alone
is insufficient to protectMusmusculus neurons from oxidative death. By contrast, structurally diverse inhibitors used at concentrations
that inhibit TG1 and TG2 simultaneously are neuroprotective. These small molecules inhibit increases in neuronal transamidating
activity inducedbyoxidative stress; they alsoprotect neuronsdownstreamofpathological ERKactivationwhenaddedwell after theonset
of the death stimulus. Together, these studies suggest thatmultiple TG isoforms, not onlyTG2, participate in oxidative stress-induced cell
death signaling; and that isoform nonselective inhibitors of TG will be most efficacious in combating oxidative death in neurological
disorders.
Introduction
Transglutaminases (TG) are an inducible family of protein cross-
linking or polyaminating enzymes that have been implicated in
diverse neurological conditions. The best-studied enzyme of the
family, TG2 (gene: Tgm2; protein: TG2), is ubiquitously ex-
pressed in the human body and is the most abundant isoform in
the brain.
A role for TG2 in neurodegeneration was first invoked as a
cross-linker of aggregated proteins in a host of diseases associated
with protein dyshomeostasis. Indeed, its transamidating activity
has been shown to be upregulated at the symptomatic stage of
Huntington’s disease (HD) (Karpuj et al., 1999; Dedeoglu et al.,
2002; Karpuj et al., 2002), Parkinson’s disease (PD) (Gibrat et al.,
2010), Alzheimer’s disease (AD) (Martin et al., 2011), cerebral
ischemia (Ientile et al., 2004), traumatic brain injury (Tolentino
et al., 2002), and spinal cord injury (Festoff et al., 2002). To
establish whether TG2 transamidating activity is causally related
to neurodegeneration, structurally diverse inhibitors have been
developed that inhibit the cysteine catalytic site. Intense interest
in TG2 has been fueled by the success of reversible broad inhibi-
tors [e.g., cyst(e)amine] that have shown durable and reproduc-
ible protective effects in in vivo models of several chronic
neurodegenerative diseases such as HD (Dedeoglu et al., 2002),
PD (Gibrat et al., 2010) and intracerebral hemorrhage (Okauchi
et al., 2009). Indeed, cystamine is in phase II studies in humans
with HD.
While a focus on TG2 has been validated by the therapeutic
success of germline deletion of TG2 in rodent models of neuro-
degenerative disease (Iismaa et al., 2009), two important issues
remain unsettled. First, isoform nonselective inhibitors result in
therapeutic benefit beyond TG2 deletion in rodentmodels of HD
(Bailey and Johnson, 2006), suggesting the possibility that other
isoforms of the TG family can compensate for deletion of a single
isoform; second, TG2 deletion does not decrease protein aggre-
gation, suggesting a more complex role for the enzyme in stress
responses (Mastroberardino et al., 2002). Indeed, current studies
implicate TG2 in diverse cellular functions, including autopha-
gosome formation (D’Eletto et al., 2009), axonal BDNF traffick-
ing (Borrell-Page`s et al., 2006), and transcriptional repression
(McConoughey et al., 2010). Accordingly, the current study was
designed with two specific goals: first, to elucidate the role, if any,
of other TG isoforms in neuronal injury; and second, to under-
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stand whether a common putative mediator of death, oxidative
stress, could induce TG message levels and activity as part of a
death cascade.
We report that multiple isoforms of TG are significantly in-
duced following stroke in vivo or oxidative stress in vitro; that
forced expression of TG1 or TG2 induces cell death in cortical
neurons; and that oxidative stress-induced cell loss in cortical
neurons can be rescued by isoform nonselective inhibitors.
Materials andMethods
Chemicals.Several structurallydifferentTGinhibitorsweretested inourmodels:
cystamine dihydrochloride (broad and reversible inhibitor, Sigma); and the ir-
reversible inhibitors B003 (Boc-DON-Gln-Ile-Val-OMe, ZediraGmbH), T101
(1,3,4,5-tetramethyl-2-[(2-oxopropyl)thio]imidazolium chloride, Zedira
GmbH),D004(1,3-dimethyl-4,5-diphenyl-2-[(2-oxopropyl)thio]imidazolium
trifluorosulfonicacid salt), and TAMRA-DON (Zedira GmbH). The MEK in-
hibitorsU0126, SL327and the inactive analogU0124 (Calbiochem)were tested
in our model. L-glutamic acid and its analog, L-homocysteic acid (HCA) were
purchased fromSigma-Aldrich.
Transient middle cerebral artery occlusion. The use of animals and
procedures were approved by the Institutional Animal Care and Use
Committees of Weill Medical College of Cornell University. Ten- to
12-week-old C57BL/6male mice were subjected to transient ischemic by
middle cerebral artery occlusion (MCAO) as previously described (Cho
et al., 2005, 2007; Kim et al., 2008). Briefly, mice were anesthetized with a
mixture of isoflurane/oxygen/nitrogen. A fiber optic probe was glued to
the parietal bone (2 mm posterior and 5 mm lateral to the bregma) and
connected to a laser-Doppler flowmeter (Periflux System 5010; Perimed)
for continuous monitoring of cerebral blood flow (CBF) in the center of
the ischemic territory. For MCAO, a 6–0 Teflon-coated black monofil-
ament surgical suture (Doccol) was inserted into the exposed external
carotid artery, advanced into the internal carotid artery, andwedged into
the cerebral arterial circle to obstruct the origin of the MCA for 30 min.
The filament was withdrawn to allow reperfusion. Lidocaine was admin-
istered during postischemia as analgesics. Using a rectal probe controlled
by a masterflex pump and thermistor temperature controller (Cole-
Parmer), animals’ body temperatures were maintained at 37  0.5°C
during MCAO and 2 h after postischemia. Only animals that exhibited
80% reduction in CBF during MCAO and80% reperfusion 10 min
following reperfusion were included in the study.
Tissue preparation after MCAO. Brains were excised, frozen, and sec-
tionedusing anunbiased stereological sampling strategy. Infarct typically
spans6mm rostrocaudal, approximately from2.8 to3.8mm from
bregma. To collect tissue to reflect the infarct area, the entire infarct
region was cryosectioned for gene expression (four sections at 50 m
thickness) and collected serially at 600 micron intervals. The sections
were cut in half and collected for each hemisphere.
Mouse embryonic fibroblasts. TG2 knock-out mice, designated
Tgm2tm1.1Rmgr (TG2/), were generated on a 129S1/Sv-ImJ back-
ground as previously described (Nanda et al., 2001). Heterozygous off-
spring were backcrossed to wild-type C57BL/6 (B6.Cg) mice for 12
generations to generate congenic heterozygous TG2/ mice with
99.95% B6.Cg-TG2/ genomic homogeneity, respectively. These
heterozygous animals were mated to generate TG2 wild-type (TG2/)
or TG2/ mice that were then set up in breeding pairs to generate
TG2/ or TG2/ embryos for experimentation. Mouse embryonic
fibroblasts (MEFs)were isolated from13.5-d-postcoitus female andmale
embryos and were cultured on DMEM/10% FCS [DMEM high glucose,
Invitrogen); 10% (v/v) fetal calf serum (Invitrogen); 400M L-glutamine
(Invitrogen); 0.2U/ml penicillin (Invitrogen); and 0.2mg/ml streptomy-
cin (Invitrogen)]. Only MEFs of passage five or lower was used for
experiments.
Primary neuronal and astrocyte cultures. Primary rat cortical neurons
were obtained from fetal Sprague Dawley rats at embryonic day 17 (E17)
as previously described (Ratan et al., 1994). Primary mouse cortical neu-
rons were obtained from C57BL/6 TG2/mice mated to generate male
and female TG2/, TG2/, or TG2/ embryos at day 15. Single em-
bryonic neuronal cultures were performed, and their genotype was re-
vealed by PCR. The astrocyte-neuronal cultures were obtained as
previously described (Haskew-Layton et al., 2010).
Genotyping. Genomic DNA for PCR was extracted from the embryos
using the DNeasy genomic DNA isolation kit (Qiagen). The TG2 wild-
type alleles were detected using the primer 5-GGAGCACACAGGCCTT
ATGAGCTGAAG-3. The TG2 knock-out alleles were detected using the
primer 5-CAGATAGGGATACAAGAAGCATTGAAG-3. As a com-
mon reverse primer, we used 5-GCCCCACAAAGGAGCAAGTGTT
ACTATGTC-3.
Cell viability. For neuronal cytotoxicity studies, cortical neurons were
plated at a density of 106 cells/ml in 96-well plates (100 l) and in 6-well
plates (3 ml), and were treated with glutamate 5 mM. Specified concen-
trations of cystamine, B003, T101, D004, and TAMRA-DONwere added
at the time of glutamate treatment. In the post-treatment experiments,
TG inhibitors were added at various time points after glutamate addition
(14, 17, 19, and 21 h), and viability was assessed 24 h later. MEF TG2/
and TG2/ cells were plated at 104 cells/ml in black 96-well plates for
16 h (/ glutamate), and live cells were visualized with calcein AM
(Invitrogen) by a Flash Cytometer (Trophos) and counted with TINA
v4.8 (Trophos). In the astrocyte-neuronal cocultures, astrocytes were
pretreated for 16 h with inhibitors at various concentrations. The drugs
were removed, and the neurons were plated on top of the astrocytes at a
concentration of 0.5  106 cells/ml in the presence or absence of the
glutamate analog HCA. Neuronal viability was measured 48 h after neu-
ronal plating by quantifying the neuronal-specific marker MAP2 using a
horseradish peroxidase/Amplex Red assay, as previously described
(Haskew-Layton et al., 2010).
RNA extraction and real-time PCR.Total RNAwas prepared from imma-
ture primary cortical neurons (E17), MEF, and brain sections, and were
reversed transcribed to cDNAwith a standard protocol. The expression lev-
els of rat andmouse Tgm1, Tgm2were quantified by real-time (RT) PCR as
previously described (McConoughey et al., 2010). The primers used in rat
samples are the following: Tgm1 (5-AGAGCACCACACCGATGAGTTT
GA-3and5-TCCGATGAGAAGCTCAAGGGCAAT-3);Tgm2(5-GCCT
TGGAACTTTGGGCAGTTTGA-3 and 5-TCATCATTGCAGTTGACC
ATGCCG-3); and -actin (5-CCATTGAACACGGCATTGTCACCA-3
and 5-GCCACACGCAGCTCATTGTAGAAA-3). The primers used in
mouse samples are the following: Tgm1 (5-TGTGGAGATCCTGCTCAG
CTACCTA-3 and 5-TGTCTGTGTCGTGTGCAGAGTTGA-3); Tgm2
(5-TTCCGGCTGACTCTGTACTTCGAG-3 and 5-ACATTGTCCTGT
TGGTCCAGCACT-3); and -actin (5-TGAACCCTAAGGCCAACC
GTGAAA-3 and5-GAGTCCATCACAATGCCTGTGGTA-3). The com-
parative cycle threshold (Ct) method was used to analyze the data from
quantitative RT-PCR. The amount of target (Tgm1 orTgm2) normalized to
an endogenous reference (-actin) and relative to a calibrator (Fig. 1A,B,
sham contralateral; Fig. 1C,D, 0 h treatment; Fig. 2C,D,TG2/) is given by
the 2Ct algorithm, also known as the delta-delta-Ct or ddCt algorithm.
The mean Ct and SD values were calculated by ABI Sequence Detection
System software version 1.4 (Applied Biosystems). Each sample was run in
triplicate, and in each experiment three or four samples per condition were
analyzed. One-way ANOVA followed by Dunnett’s post hoc test was calcu-
lated in Prism (GraphPad Software).
Measurement of endogenous transamidating activity. For the glutamate
treatments, cells were treated at different time points (4, 8, and 12 h) and
cotreated with cystamine (100M), B003 (200M), D004 (50M), T101
(50 M), U0126 (10 M), U0124 (10 M), and SL327 (10 M) for 12 h.
The lysine donor biotin pentylamine (BPA; 500M) (Thermo Scientific)
was added to the media at the same time. Cells were lysed in hypotonic
buffer (10mMTris-HCl pH8, 1mMKCl, 1mMMgCl2). Equal amounts of
proteins were loaded in a Bio-Dot Apparatus (Bio-Rad). Extracellular
proteins were harvested from the media and centrifuged at 21,000 g at
4°C for 10 min and then 100 l per sample was loaded into the Bio-Dot
Apparatus. The nitrocellulose membrane was probed for streptavidin
and actin (loading control). The dot densitometry was calculated with
the Odyssey software (Integrated Intensity, LI-COR Bioscience).
TG1 and TG2 overexpression. Human TG2 and TG1 or EGFP se-
quences were introduced into cortical neurons (E17) using the Amaxa
Rat neuron Nucleofector Kit (Lonza). The next day, TG2, TG1, and
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EGFP overexpression was confirmed by Western blot, and cell survival
was measured by MTT.
TG2 antibody.We produced a specific custom rabbit monoclonal an-
tibody (Epitomics), using recombinant mouse TG2 as immunogen.
Specificity is shown in Figure 2D.
Immunoblot analysis. Protein extracts were obtained using 1% Triton
buffer. Antibodies against Myc-tag (9E10, Covance), EGFP (Molecular
Probes), TG2 (custom made), TG1 (Abcam), and -actin (AC-74;
Sigma-Aldrich) were diluted 1:1000, 1:2000; 1:1000; 1:1000, and
1:10,000, respectively. Proteins were detected using an Odyssey infrared
imaging system (LI-COR Biosciences).
Statistical analysis. Statistical analysis was conducted by two-way
ANOVA followed by Bonferroni’s post hoc test or one-way ANOVA fol-
lowed by Dunnett’s post hoc test. Statistically significant results were
defined as follows: *p 	 0.05; **p 	 0.01; and ***p 	 0.001. All the
experiments presented here were repeated at least three times.
Results
Multiple TGs are induced following stroke in vivo or
neuronal oxidative stress in vitro
TG inhibition has been shown to reduce damage in hemorrhagic
(Okauchi et al., 2009) and ischemic stroke models (Tolentino et
al., 2004; Hwang et al., 2009), but an analysis of how message
levels of distinct TG isoforms change following ischemic stroke
has not been performed. We analyzed a temporal profile of
mRNA expression of six of the nine knownTG isoforms from the
ipsilateral hemisphere of rodents that underwent focal brain isch-
emia (MCAO; sham, and 6, 24, and 72 h after reperfusion). As
expected, Tgm2 message levels were significantly induced in the
ipsilateral hemisphere (Fig. 1A). Surpris-
ingly, however, we also found a100-fold
increase in Tgm1, which peaked 72 h after
the onset of ischemia (Fig. 1B).
As stroke-induced damage is charac-
terized by nitrosative (Samdani et al.,
1997) and oxidative stress (Chen et al.,
2011), we used the experimental leverage
of a well established in vitro model in
cortical neurons. In this model, gluta-
mate simulates oxidative stress via a non-
receptor-mediated mechanism involving
the inhibition of plasma membrane cys-
tine transport and depletion of the versa-
tile antioxidant glutathione (Ratan et al.,
1994). Prior studies have shown the utility
of this model for studying stroke patho-
genesis and treatment (Siddiq et al., 2005;
Langley et al., 2008). As expected, not only
Tgm2, but also Tgm1 message levels were
induced in a manner qualitatively similar
to that found following stroke in vivo (Fig.
1C,D).
Conflicting data have been presented
about the role of TGs in modulating cell
death (Piacentini et al., 2011). However,
most of the studies implicating TG2 as a
positive modulator of survival have been
performed in transformed cancer cells,
not in primary neurons. To determine
whether TG1 or TG2 is sufficient to in-
duce cell death, we transfected immature
cortical neurons with human TG1, TG2,
or EGFP as control (Amaxa, Lonza). We
verified expression of TG1, TG2, or EGFP
in separate experiments 24 h after trans-
fection by immunoblot (Fig. 1E). Moreover, as monitored by
morphological (phase contrast) or metabolic (MTT assay) crite-
ria, overexpression of TG1 or TG2 is sufficient to induce neuro-
nal cell death (Fig. 1F). Of note, transfection of the two isoforms
together, which resulted in the same levels of each isoform as
when they are expressed individually, did not enhance cell death.
These results show that TG1 and TG2 are sufficient to induce
neuronal death, and suggest that they work via a similar path-
way, as their effects at this level of expression are not additive
or synergistic.
Our findings suggested that TG1 and TG2 might work redun-
dantly to ensure the death of neurons following oxidative death. To
establish whether TG activity is necessary for oxidative death, we
took advantage of germline knockouts of TG2 (TG2/). Animals
deficient in this isoform have shown smaller infarct volumes in
stroke (Colak and Johnson, 2012) or resistance to the deleterious
effects of mutant huntingtin (Mastroberardino et al., 2002; Bailey
and Johnson, 2006). However, germline knockout of TG2 was not
sufficient to protect cortical neurons fromoxidative stress (Fig. 2A);
but its complete absence in mouse embryonic fibroblasts (cultured
from TG2/mice) increased resistance to glutamate-induced oxi-
dative stress (Fig. 2B).TheabilityofTG1andTG2 to inducedeathof
cortical neurons raised the possibility that cortical neurons were in-
sensitive to TG2 deletion because of compensatory upregulation of
TG1, whereas MEFs were sensitive to TG2 deletion because of the
absence of TG1 compensation. Consistent with this model, we
foundthatTG1is induced inglutamate-treatedcorticalneurons that
Figure 1. TG1 and TG2 mRNA levels are upregulated in a focal model of stroke (MCAO) and in an in vitro model of neuronal
oxidative stress, and they are sufficient to induce cell death.A,B, Temporal expression profile for Tgm2 (A) and Tgm1 (B) inMCAO.
Both of the genes are significantly upregulated in the ipsilateral side comparedwith the contralateral hemisphere (***p	0.001).
A similar upregulation is revealed in an in vitro model of oxidative stress. C, D, Tgm2 (C) and Tgm1 (D) levels are significantly
upregulated 12 h after glutamate (5 mM) exposure in rat neurons (**p	 0.01; ***p	 0.0001 compared with the relative
glutamate 0 h). E, F, Forced expression of TG1 and/or TG2 (E) exerts neuronal toxicity, as revealed by MTT (F ). Significant toxicity
compared with EGFP expression. **p	 0.01. EGFP-expressing cells are calculated at 100% survival.
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are TG2/ (Fig. 2C) but not in glutamate-
treatedMEFs that are TG2/ (Fig. 2D).
Intracellular transglutaminase
transamidating activity is increased
following oxidative stress and
structurally diverse TG inhibitors
protect neurons from oxidative
stress-driven cell death
To establishwhetherTG1 andTG2are both
necessary for oxidative neuronal death, we
used a set of structurally diverse small mol-
ecules whose commonality is that they in-
hibit the transamidating site cysteine inboth
TG1 and TG2 (Griffin et al., 2002). The use
of diverse compounds makes it likely if
common biological effects are observed,
that these effects can be attributed to inhibi-
tion of the transamidating activity of TGs,
rather than to an off-target effect of any one
class of compounds.Moreover, use of small
molecules allows us to target the transami-
dating activitywithout affectingTGGTPase
activity or other domains. Before testing the
compounds, we verified that the transami-
dating activity is increased following oxida-
tive stress using BPA, a lysine donor whose
incorporation into protein has been shown
to be dependent on transamidating activity
(Fig. 3) (Lee et al., 1992).
We first evaluated the effect of a com-
monly used TG inhibitor, cystamine, that
was recently shown not to have significant
preference for TG2 over TG1 or TG3 in in
vitroassays (Schaertl et al., 2010).Cystamine
is the disulfide form of the free thiol cys-
teamine, and it reversibly inhibits TG activ-
ity by acting as an alternative substrate for
the enzyme. It is therefore considered as a
pseudo-inhibitor substrate (Fig. 4A). As ex-
pected, we found that cystamine not only
inhibited TG activity (Fig. 5A,B), but also
potently protected cortical neurons from
oxidative death (Fig. 4B). As cystamine has
been showntohaveoff-target effects includ-
ing caspase inhibition (Lesort et al., 2003), we tested an irreversible
peptide inhibitor, B003, which has similar IC50 values for recombi-
nant TG1 (1.1M) as those for TG2 (0.3M), but almost no activity
towardcaspase3 (McConougheyet al., 2010).B003 formsacovalent
bond with cysteine in the active site and is channeled specifically to
TGby the amino acids that surround the reactiveDONmoiety (Fig.
4A). Similar to cystamine, B003 protected cortical neurons from
oxidative death (Fig. 4C) and reduced cell associated transamidating
activity (Fig. 5A,B). Together, these structurally diverse, isoform-
nonselectiveTG inhibitors suggest that the transamidating activity is
necessary for thedeathof corticalneurons in response toglutathione
depletion.
Inhibition of intracellular but not extracellular
transamidating activity protects neurons from oxidative
stress
By contrast to our study, a prior study in non-neural cells failed to
show that B003 could inhibit cell-based TG activity, raising the
Figure 2. TG2 is necessary for oxidative death in MEFs but not cortical neurons. Resistance of cortical neurons to TG2 knockout
is associated with compensatory upregulation of Tgm1. A, B, TG2/ in single embryonic neuronal cultures (A) and in MEFs (B)
and relative MTT assay. TG2 deletion in MEFs significantly protects against glutamate-induced death. *p	 0.05; **p	 0.01;
***p	 0.001 compared with TG2/MEFs; untreated controls are calculated at 100% of survival. C,D, Tgm1 levels are induced
after 12 h of glutamate treatment in mouse neurons (C) (***p	 0.001 compared with controls), but not in MEFs (D).
Figure 3. Intracellular TG transamidating activity is increased upon glutamate treatment.
Endogenous transamidating activity is significantly increased after 12hof glutamate treatment
compared with control by dot blot assay. **p	 0.01.
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possibility that extracellular TG might contribute to death
(Schaertl et al., 2010). Indeed, TG2 can be secreted to exert bio-
logical changes on the extracellular matrix (Belkin, 2011). To
establish whether TG activity must be inhibited intracellularly,
extracellularly, or both to induce neuroprotection, we took ad-
vantage of two structurally similar inhibitors, D004 and T101
(Fig. 4A), where the nucleophilic thiol of the active site attacks
the carbon between the sulfur and the carbonyl group, leading to
an irreversible TG2 acetonylation. The compounds differ in their
membrane permeability. T101 has two methyl groups, while
D004 presents two phenyl groups. Accordingly, D004 is more
hydrophobic, and it tends to penetrate preferentially into cells. As
expected, the hydrophilic T101 was recently shown to act only
extracellularly (Antonyak et al., 2011). We tested these com-
pounds in our system and found that only the cell-permeable TG
inhibitor D004 exerted dose-dependent protection against gluta-
Figure 4. TG inhibition protects immature cortical neurons from oxidative stress-mediated cell death. A, Structures of four diverse, reversible or irreversible, isoform-nonselective TG inhibitors
tested in an in vitromodel of oxidative stress. B–D, Cystamine (1–100M) (B), B003 (100, 200M) (C), and D004 (25–100M) (D) protect primary immature cortical neurons against oxidative
stress-induced cell death. E, T101, a cell-impermeable TG inhibitor, fails to provide protection. **p	 0.01; ***p	 0.001 compared with glutamate treatment alone; untreated controls are
calculated at 100% of survival.
Figure 5. Inhibition of intracellular TG activity correlates with neuroprotection. A, All inhibitors tested are able to significantly reduce extracellular transamidating activity (A). A,B, T101 fails to
inhibit intracellular TG transamidating activity. B, All the protective inhibitors are able to significantly downregulate TG2 activity to control levels. C, TAMRA-DON, a peptide-based, fluorescent
inhibitor analog to B003, enters the cells (10–100M) (top), and it protects against oxidative stress (100M) (bottom). **p	 0.01 comparedwith glutamate treatment alone; untreated controls
are calculated at 100% of survival.
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mate toxicity (Fig. 4D). T101 failed to in-
hibit intracellular activity (Fig. 5A,B) and
was not able to protect neurons from glu-
tamate toxicity at any of the concentra-
tions tested (Fig. 4E). We conclude that
cystamine, B003, and D004 all inhibit
intracellular TG in neurons to exert pro-
tection fromoxidative stress. This conclu-
sion was further reinforced by two
additional observations: first, the ability
to detect a fluorescently conjugated
peptide-based inhibitor, TAMRA-DON, to
penetrate inside neurons in a dose-de-
pendentmanner (Fig. 5C, top) and the abil-
ity of this inhibitor to protect against
oxidative stress at 100M(Fig. 5C, bottom);
and second, the ability of TG inhibitors to
protect hippocampal neuroblasts (grown in
the absence of astrocytes) from oxidative
death (data not shown). Our results do not
exclude the possibility that both extracellu-
lar and intracellularTGmustbe inhibited to
protect neurons.
A recent study from our group showed
that low, protective doses of hydrogen
peroxide can induce a “state” change in
astrocytes that facilitates their ability to
protect adjacent neurons from glutathi-
one depletion-induced death (Haskew-
Layton et al., 2010). A targetedmicroarray
demonstrated that Tgm2 was among the
small number of genes whose downregu-
lation correlated with neuroprotection
(Haskew-Layton et al., 2010). To deter-
mine whether TG inhibition in astrocytes
can non-cell autonomously protect neu-
rons, we pretreated astrocytes with the
isoform-nonselective TG inhibitors cysta-
mine or B003. The inhibitors were washed
off, cortical neurons were added, and the
coculture was exposed to the glutamate
analog HCA. Without pretreatment with
the TG inhibitors, a substantial number of
neurons died in response to the glutamate
analog (Fig. 6A–C; HCA treatments). In
contrast, TG inhibition in astrocytes led to
a significant sparing of the neurons (Fig.
6A–C; cystamine and B003 treatments).
These findings demonstrate that TG inhi-
bition in neurons or astrocytes is suffi-
cient to confer resistance to oxidative death.
Inhibition of the ERK pathway suppresses TG2 activation
Previous studies from our laboratory and others have shown that
glutathione levels reach a steady state (60% below control) at
6 h following glutamate treatment (Zaman et al., 1999). Cells
become irreversibly committed to cell death much later, around
18 h. The increase of TGs transcription and activity within 8–12
h after glutamate exposure raised the possibility that TG inhibi-
tion, well after the onset of glutamate treatment, would suppress
increased TG activity and protect neurons downstream of gluta-
thione depletion. Indeed, addition of the cell-permeant TG in-
hibitors (cystamine 100 M, B003 100 M, D004 50 M) up to
14–17 h after glutamate treatment, completely protected neu-
rons from cell death (Fig. 7A), and this protection happened
without an effect on glutathione depletion by glutamate (data not
shown). TG inhibitors can thus be used well after depletion of
glutathione and still protect neurons, and this may, in part, ex-
plain their effectiveness inmultiple diseasemodels. Increased TG
activity well after the onset of oxidative stress and just before the
cells are irreversibly committed to death led us to ask whether TG
transamidating activity lies upstream or downstream of events
known to be causally related to oxidative death that occur just
before cell death commitment. Among the signaling molecules
defined, the ERK family of kinases caught our attention. Prior
elegant work from Ho et al. (2007) revealed a delayed and sus-
Figure 6. TG inhibition in astrocytes non-cell autonomously protects neurons. A, B, Astrocytes are treated overnight with the TG
inhibitors Cystamine (A) or B003 (B). Followingwashoff of the inhibitors, neuronswereplatedwith orwithout theglutamate analogHCA
(5mM) for 48h: *p	0.05; **p	0.01neuronal survival comparedwithglutamate treatmentalone, untreated controls are calculatedat
100%of survival. C, Representative phase contrast pictures forA andB; cystamine, 200M; B003, 150M.
Figure 7. TG transamidating activity is a downstream target of the ERK pathway. A, TG inhibitors exerted protection when
added up to 14–17 h post-glutamate exposure. B–D, Glutamate induces phosphorylated ERK (pERK) (B); MEK inhibitors U0126
and SL327 block pERK activation (B) and protect against glutamate toxicity (C) by reducing TG activation to the control level (D).
*p	 0.05; **p	 0.01 compared with glutamate treatment alone; untreated controls are calculated at 100% of survival. U0124
is a negative control for U0126.
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tained activation of ERK1/2 owing to redox-mediated MKP-1
(MAPK phosphatase 1) or PP2A [4-amino-5-(4-chlorophenyl)-
7-(t-butyl)pyrazolo[3,4-d]pyrimidine] inhibition. Intriguingly,
prior data also suggest that ERK can activate TGs (Akimov and
Belkin, 2003), and the transamidating activity may induce het-
erodimerization of ERK proteins into a complex in the nucleus
(Lundquist and Dudek, 2006). We thus examined whether TG
activity is downstream of pathological ERK activation in gluta-
thione depletion-induced oxidative stress. To understand the re-
lationship between TG activity and sustained ERK activation, we
examined TG activity in the presence of a well established
MEK1/2 (which works upstream of ERK) inhibitor U0126, its
structurally similar but inactive analog U0124, and a brain-
permeantMEK inhibitor, SL327 (Wang et al., 2003). These com-
pounds were tested for activity (Fig. 7B) and protection (Fig. 7C)
in our system.U0124 failed to blockMEK (Fig. 7B) activation and
failed to protect cells from oxidative stress (Fig. 7C). As expected,
we found that protective concentrations of U0126 and SL327
significantly reduced TG activity and U0124 did not (Fig. 7D).
Moreover, U0126 does not prevent death mediated by forced TG
expression (data not shown). Altogether these findings place TG
activity downstream of pathological ERK activation in the oxida-
tive stress cascade and suggest that TGmay be a distal point in the
affector pathway of oxidative death.
Discussion
Most schemes for TG’s role in acute and chronic neurodegenera-
tion have centered around the ability of these enzymes to cross-
link mutated and/or accumulated proteins in a host of diseases,
including AD, HD, and PD (Caccamo et al., 2010). And while this
model unifies diseases associated with proteotoxicity, it fails to ac-
count for the benefits of molecular or pharmacological TG deletion
in ischemic (Hwang et al., 2009; Colak et al., 2011) or hemorrhagic
stroke (Okauchi et al., 2009). Indeed, excitingnewdataon the roleof
TG in autophagosome formation (D’Eletto et al., 2009), in inhibit-
ing axonal transport of growth factors such as BDNF (Borrell-Page`s
et al., 2006), in repressing adaptive gene expression (McConoughey
et al., 2010), and on influencing nuclear actin dynamics (Munsie et
al., 2011)have focused attentiononbiological roles of these fascinat-
ing enzymesother thancross-linking.Here,wedemonstrate thatTG
is anecessary componentof oxidative stress-induceddeath signaling
in cortical neurons (Figs. 4–6). As oxidative stress has been impli-
cated in almost every neurological condition, the findings suggest
that even in diseases characterized by proteotoxicity TG’smajor role
may not be limited to cross-linking but also may include cell death
signaling.
Because of TG2’s abundance in the brain, its transcriptional in-
duction in a host of disease states, and the neuroprotective effects of
its germline deletion, there has been almost exclusive focus on this
isoform as a perpetrator of neuronal loss. Our results in a model of
stroke invivoand inamodelofoxidative stress invitroamplify recent
studies by others showing that in addition to TG2, TG1 is also dra-
matically regulated by ischemia and/or oxidative stress. Unexpect-
edly, we showed that TG1 was as effective in inducing death in
corticalneuronsasTG2(Fig.1).Theresultshelp toexplain thebroad
salutary effects of currently available small-molecule inhibitors of
TG including in our in vitromodel of oxidative stress, as all of these
have been shown to inhibit TG1, TG2, and other TG isoforms
(Schaertl et al., 2010). They also provide one explanation for why in
the R6/2 mouse model of HD isoform-nonselective TG inhibition
prolongs survival (19.8%) longer than germline deletion of TG2
(12%) (Bailey and Johnson, 2006). Future studies will examine the
effect of dual TG1 and TG2 deletion on disease outcomes inmodels
of stroke andHD.
TGs have been implicated in oxidative stress-induced death
outside of the nervous system, but most of these studies, which
implicate TG as an inhibitor of cell death, involve the addition of
nonphysiological oxidants to non-neural cells. By contrast, the
model we used in this study involves depletion of the versatile
cellular antioxidant, glutathione—a theoretically more physio-
logical way to induce an imbalance in oxidants and antioxidants
above a toxic threshold, the operational definition of “oxidative
stress.” Indeed, exposure of enriched cultures of neurons or
astrocyte-neuronal cocultures to high concentrations of gluta-
mate or glutamate analog (5 mM) leads to selective degeneration
of neurons over 24–48 h (Murphy et al., 1989; Haskew-Layton et
al., 2010). In this paradigm, glutamate toxicity results not from
hyperactivation of ionotropic glutamate receptors, but rather via
competitive inhibition of cyst(e)ine transport, leading to dimin-
ished glutathione levels and oxidative death. Accordingly, neu-
rons undergo antioxidant-responsive activation of an ERK-
dependent, caspase-independentcelldeathmechanismthat involves
12-lipoxygenase, truncated BH3 interacting domain (tBID) and
apoptosis-inducing factor (AIF); Seiler et al., 2008. Of note, dis-
rupted calcium homeostasis, which would be expected to activate
TGs, has also been implicated inoxidative glutamate toxicity (Tan et
al., 1998); our findings place TG activation as an event downstream
of ERK signaling, but before cell death commitment. Indeed, ERK
inhibitors cannot block death due to forced expression of TG2. In
conjunctionwiththefindingsherein,recentstudiesfromourlaboratory
(McConoughey et al., 2010) suggest that TGacts to repress prosurvival
gene expression to ensure oxidative death; but our studies do not pre-
clude a role for TG in the effector pathway of death following glutathi-
one depletion in cortical neurons, includingAIF translocation.
The in vitro model of oxidative death used in this study has
been used by many laboratories to identify a number of targets
whose inhibition is protective from stroke (Siddiq et al., 2005),
HD (Ferrante et al., 2003, 2004), PD (Lee et al., 2009), or AD
(Sagara et al., 1998) in vivo, including hypoxia-inducible factor
prolyl hydroxylases (Siddiq et al., 2005), class I and II histone
deacetylases (Langley et al., 2008), activating transcription
factor-4 (Lange et al., 2008), Sp1 (Ryu et al., 2003; Sleiman et al.,
2011), Myc (Sleiman et al., 2011), and Keap (a negative regulator
of Nrf2) (Smirnova et al., 2011). Indeed, we found a similar in-
duction of Tgm1 and Tgm2 levels in cortical neurons undergoing
oxidative death as we did in the ipsilateral hemisphere following
stroke (Fig. 1). Although our in vivo studies do not distinguish
neuronal versus non-neural activation of TG, we present in vitro
data showing that inhibition of TG in astrocytes or neurons can
abrogate neuronal oxidative death (Figs. 4–6).
In conclusion,our studyhighlights the role thatoxidative stress, a
putative mediator of many neurological conditions, can play in ac-
tivatingmultiple TG isoforms downstreamof pathological ERK sig-
naling. The findings provide a unifying model for the role of TG in
numerous neurological conditions, and the broad salutary effects of
isoform-nonselective TG inhibitors. As ERK has both physiological
and pathological roles (Chu et al., 2004), we propose that TG inhi-
bition represents a more specific way to inhibit pathological ERK
signaling without affecting physiologically important ERK activa-
tion downstream of growth factor receptor activation.
References
Akimov SS, Belkin AM (2003) Opposing roles of Ras/Raf oncogenes and the
MEK1/ERK signaling module in regulation of expression and adhesive
function of surface transglutaminase. J Biol Chem 278:35609–35619.
Basso et al. • Transglutaminase1, 2, and Neuronal Oxidative Stress J. Neurosci., May 9, 2012 • 32(19):6561–6569 • 6567
AntonyakMA, Li B, Boroughs LK, Johnson JL,Druso JE, BryantKL,Holowka
DA, Cerione RA (2011) Cancer cell-derived microvesicles induce trans-
formation by transferring tissue transglutaminase and fibronectin to re-
cipient cells. Proc Natl Acad Sci U S A 108:4852–4857.
Bailey CD, Johnson GV (2006) The protective effects of cystamine in the
R6/2 Huntington’s disease mouse involve mechanisms other than the
inhibition of tissue transglutaminase. Neurobiol Aging 27:871–879.
Belkin AM (2011) Extracellular TG2: emerging functions and regulation.
FEBS J 278:4704–4716.
Borrell-Page`s M, Canals JM, Cordelie`res FP, Parker JA, Pineda JR, Grange G,
Bryson EA, Guillermier M, Hirsch E, Hantraye P, CheethamME, Ne´ri C,
Alberch J, Brouillet E, Saudou F, Humbert S (2006) Cystamine and cys-
teamine increase brain levels of BDNF in Huntington disease via HSJ1b
and transglutaminase. J Clin Invest 116:1410–1424.
Caccamo D, Curro` M, Condello S, Ferlazzo N, Ientile R (2010) Critical role
of transglutaminase and other stress proteins during neurodegenerative
processes. Amino Acids 38:653–658.
Chen SD, Yang DI, Lin TK, Shaw FZ, Liou CW, Chuang YC (2011) Roles of
oxidative stress, apoptosis, PGC-1alpha and mitochondrial biogenesis in
cerebral ischemia. Int J Mol Sci 12:7199–7215.
Cho S, Park EM, FebbraioM, Anrather J, Park L, Racchumi G, Silverstein RL,
Iadecola C (2005) The class B scavenger receptor CD36 mediates free
radical production and tissue injury in cerebral ischemia. J Neurosci
25:2504–2512.
Cho S, Szeto HH, Kim E, Kim H, Tolhurst AT, Pinto JT (2007) A novel
cell-permeable antioxidant peptide, SS31, attenuates ischemic brain in-
jury by down-regulating CD36. J Biol Chem 282:4634–4642.
ChuCT, Levinthal DJ, Kulich SM, Chalovich EM,DeFrancoDB (2004) Ox-
idative neuronal injury. The dark side of ERK1/2. Eur J Biochem
271:2060–2066.
Colak G, Johnson GV (2012) Complete transglutaminase 2 ablation results
in reduced stroke volumes and astrocytes that exhibit increased survival in
response to ischemia. Neurobiol Dis 45:1042–1050.
Colak G, Keillor JW, Johnson GV (2011) Cytosolic guanine nucledotide
binding deficient form of transglutaminase 2 (R580a) potentiates cell
death in oxygen glucose deprivation. PLoS One 6:e16665.
Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW,
Matson WR, Cooper AJ, Ratan RR, Beal MF, Hersch SM, Ferrante RJ
(2002) Therapeutic effects of cystamine in a murine model of Hunting-
ton’s disease. J Neurosci 22:8942–8950.
D’Eletto M, Farrace MG, Falasca L, Reali V, Oliverio S, Melino G, Griffin M,
Fimia GM, Piacentini M (2009) Transglutaminase 2 is involved in au-
tophagosome maturation. Autophagy 5:1145–1154.
Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall
NW, Ratan RR, Luthi-Carter R, Hersch SM (2003) Histone deacetylase
inhibition by sodium butyrate chemotherapy ameliorates the neurode-
generative phenotype in Huntington’s disease mice. J Neurosci
23:9418–9427.
Ferrante RJ, Ryu H, Kubilus JK, D’Mello S, Sugars KL, Lee J, Lu P, Smith K,
Browne S, Beal MF, Kristal BS, Stavrovskaya IG, Hewett S, Rubinsztein
DC, Langley B, Ratan RR (2004) Chemotherapy for the brain: the anti-
tumor antibiotic mithramycin prolongs survival in a mouse model of
Huntington’s disease. J Neurosci 24:10335–10342.
Festoff BW, SantaCruz K, Arnold PM, Sebastian CT, Davies PJ, Citron BA
(2002) Injury-induced “switch” from GTP-regulated to novel GTP-
independent isoform of tissue transglutaminase in the rat spinal cord.
J Neurochem 81:708–718.
Gibrat C, Bousquet M, Saint-Pierre M, Le´vesque D, Calon F, Rouillard C,
Cicchetti F (2010) Cystamine prevents MPTP-induced toxicity in
young adultmice via the up-regulation of the brain-derived neurotrophic
factor. Prog Neuropsychopharmacol Biol Psychiatry 34:193–203.
Griffin M, Casadio R, Bergamini CM (2002) Transglutaminases: nature’s
biological glues. Biochem J 368:377–396.
Haskew-Layton RE, Payappilly JB, Smirnova NA,Ma TC, Chan KK,Murphy
TH, Guo H, Langley B, Sultana R, Butterfield DA, Santagata S, Alldred
MJ, Gazaryan IG, Bell GW, Ginsberg SD, Ratan RR (2010) Controlled
enzymatic production of astrocytic hydrogen peroxide protects neurons
from oxidative stress via an Nrf2-independent pathway. Proc Natl Acad
Sci U S A 107:17385–17390.
Ho Y, Logue E, Callaway CW, DeFranco DB (2007) Different mechanisms
account for extracellular-signal regulated kinase activation in distinct
brain regions following global ischemia and reperfusion. Neuroscience
145:248–255.
Hwang IK, YooKY, Yi SS, Kim IY,HwangHS, Lee KY, Choi SM, Lee IS, Yoon
YS, Kim SY,WonMH, Seong JK (2009) Expression of tissue-type trans-
glutaminase (tTG) and the effect of tTG inhibitor on the hippocampal
CA1 region after transient ischemia in gerbils. Brain Res 1263:134–142.
Ientile R, Caccamo D, Marciano MC, Curro` M, Mannucci C, Campisi A,
Calapai G (2004) Transglutaminase activity and transglutaminase
mRNA transcripts in gerbil brain ischemia. Neurosci Lett 363:173–177.
Iismaa SE, Mearns BM, Lorand L, Graham RM (2009) Transglutaminases
and disease: lessons from genetically engineered mouse models and in-
herited disorders. Physiol Rev 89:991–1023.
Karpuj MV, Garren H, Slunt H, Price DL, Gusella J, Becher MW, Steinman L
(1999) Transglutaminase aggregates huntingtin into nonamyloidogenic
polymers, and its enzymatic activity increases in Huntington’s disease
brain nuclei. Proc Natl Acad Sci U S A 96:7388–7393.
Karpuj MV, Becher MW, Steinman L (2002) Evidence for a role for trans-
glutaminase in Huntington’s disease and the potential therapeutic impli-
cations. Neurochem Int 40:31–36.
Kim E, Tolhurst AT, Qin LY, Chen XY, Febbraio M, Cho S (2008) CD36/
fatty acid translocase, an inflammatory mediator, is involved in
hyperlipidemia-induced exacerbation in ischemic brain injury. J Neuro-
sci 28:4661–4670.
Lange PS, Chavez JC, Pinto JT, Coppola G, SunCW, Townes TM,Geschwind
DH, Ratan RR (2008) ATF4 is an oxidative stress-inducible, prodeath
transcription factor in neurons in vitro and in vivo. J Exp Med
205:1227–1242.
Langley B, D’AnnibaleMA, Suh K, Ayoub I, Tolhurst A, Bastan B, Yang L, Ko
B, Fisher M, Cho S, Beal MF, Ratan RR (2008) Pulse inhibition of his-
tone deacetylases induces complete resistance to oxidative death in corti-
cal neurons without toxicity and reveals a role for cytoplasmic p21(waf1/
cip1) in cell cycle-independent neuroprotection. J Neurosci 28:163–176.
Lee DW, Rajagopalan S, Siddiq A, Gwiazda R, Yang L, Beal MF, Ratan RR,
Andersen JK (2009) Inhibition of prolyl hydroxylase protects against
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity:
model for the potential involvement of the hypoxia-inducible factor path-
way in Parkinson disease. J Biol Chem 284:29065–29076.
Lee KN, Maxwell MD, Patterson MK Jr, Birckbichler PJ, Conway E (1992)
Identification of transglutaminase substrates in HT29 colon cancer cells:
use of 5-(biotinamido)pentylamine as a transglutaminase-specific probe.
Biochim Biophys Acta 1136:12–16.
Lesort M, Lee M, Tucholski J, Johnson GV (2003) Cystamine inhibits
caspase activity. Implications for the treatment of polyglutamine disor-
ders. J Biol Chem 278:3825–3830.
Lundquist JJ, Dudek SM (2006) Differential activation of extracellular
signal-regulated kinase 1 and a related complex in neuronal nuclei. Brain
Cell Biol 35:267–281.
Martin A, De Vivo G, Gentile V (2011) Possible role of the transglutami-
nases in the pathogenesis of Alzheimer’s disease and other neurodegen-
erative diseases. Int J Alzheimers Dis 2011:865432.
Mastroberardino PG, Iannicola C, Nardacci R, Bernassola F, De Laurenzi V,
Melino G, Moreno S, Pavone F, Oliverio S, Fesus L, Piacentini M (2002)
“Tissue” transglutaminase ablation reduces neuronal death and prolongs
survival in a mouse model of Huntington’s disease. Cell Death Differ
9:873–880.
McConoughey SJ, Basso M, Niatsetskaya ZV, Sleiman SF, Smirnova NA,
Langley BC, Mahishi L, Cooper AJ, Antonyak MA, Cerione RA, Li B,
Starkov A, Chaturvedi RK, Beal MF, Coppola G, Geschwind DH, Ryu H,
Xia L, Iismaa SE, Pallos J, et al (2010) Inhibition of transglutaminase 2
mitigates transcriptional dysregulation in models of Huntington disease.
EMBOMol Med 2:349–370.
Munsie L, Caron N, Atwal RS, Marsden I, Wild EJ, Bamburg JR, Tabrizi SJ,
Truant R (2011) Mutant huntingtin causes defective actin remodeling
during stress: defining a new role for transglutaminase 2 in neurodegen-
erative disease. HumMol Genet 20:1937–1951.
Murphy TH, Miyamoto M, Sastre A, Schnaar RL, Coyle JT (1989) Gluta-
mate toxicity in a neuronal cell line involves inhibition of cystine trans-
port leading to oxidative stress. Neuron 2:1547–1558.
Nanda N, Iismaa SE, Owens WA, Husain A, Mackay F, Graham RM (2001)
Targeted inactivation of Gh/tissue transglutaminase II. J Biol Chem
276:20673–20678.
OkauchiM, Xi G, Keep RF, Hua Y (2009) Tissue-type transglutaminase and
6568 • J. Neurosci., May 9, 2012 • 32(19):6561–6569 Basso et al. • Transglutaminase1, 2, and Neuronal Oxidative Stress
the effects of cystamine on intracerebral hemorrhage-induced brain
edema and neurological deficits. Brain Res 1249:229–236.
Piacentini M, D’Eletto M, Falasca L, Farrace MG, Rodolfo C (2011) Trans-
glutaminase 2 at the crossroads between cell death and survival. Adv
Enzymol Relat Areas Mol Biol 78:197–246.
Ratan RR, Murphy TH, Baraban JM (1994) Oxidative stress induces apo-
ptosis in embryonic cortical neurons. J Neurochem 62:376–379.
Ryu H, Lee J, Zaman K, Kubilis J, Ferrante RJ, Ross BD, Neve R, Ratan RR
(2003) Sp1 and Sp3 are oxidative stress-inducible, antideath transcrip-
tion factors in cortical neurons. J Neurosci 23:3597–3606.
Sagara Y, Dargusch R, Chambers D, Davis J, Schubert D, Maher P (1998)
Cellular mechanisms of resistance to chronic oxidative stress. Free Radic
Biol Med 24:1375–1389.
Samdani AF, Dawson TM, Dawson VL (1997) Nitric oxide synthase in
models of focal ischemia. Stroke 28:1283–1288.
Schaertl S, Prime M, Wityak J, Dominguez C, Munoz-Sanjuan I, Pacifici RE,
Courtney S, Scheel A, Macdonald D (2010) A profiling platform for the
characterization of transglutaminase 2 (TG2) inhibitors. J Biomol Screen
15:478–487.
Seiler A, Schneider M, Fo¨rster H, Roth S, Wirth EK, Culmsee C, Plesnila N,
Kremmer E, Rådmark O, Wurst W, Bornkamm GW, Schweizer U, Con-
rad M (2008) Glutathione peroxidase 4 senses and translates oxidative
stress into 12/15-lipoxygenase-dependent- and AIF-mediated cell death.
Cell Metab 8:237–248.
Siddiq A, Ayoub IA, Chavez JC, Aminova L, Shah S, LaManna JC, Patton SM,
Connor JR, Cherny RA, Volitakis I, Bush AI, Langsetmo I, Seeley T, Gun-
zler V, Ratan RR (2005) Hypoxia-inducible factor prolyl 4-hydroxylase
inhibition. A target for neuroprotection in the central nervous system.
J Biol Chem 280:41732–41743.
Sleiman SF, Langley BC, Basso M, Berlin J, Xia L, Payappilly JB, Kharel MK,
Guo H, Marsh JL, Thompson LM, Mahishi L, Ahuja P, MacLellan WR,
Geschwind DH, Coppola G, Rohr J, Ratan RR (2011) Mithramycin is a
gene-selective Sp1 inhibitor that identifies a biological intersection be-
tween cancer and neurodegeneration. J Neurosci 31:6858–6870.
Smirnova NA, Haskew-Layton RE, Basso M, Hushpulian DM, Payappilly JB,
Speer RE, AhnYH, Rakhman I, Cole PA, Pinto JT, Ratan RR,Gazaryan IG
(2011) Development of Neh2-luciferase reporter and its application for
high throughput screening and real-time monitoring of Nrf2 activators.
Chem Biol 18:752–765.
Tan S, Sagara Y, Liu Y, Maher P, Schubert D (1998) The regulation of reac-
tive oxygen species production during programmed cell death. J Cell Biol
141:1423–1432.
Tolentino PJ, DeFord SM,Notterpek L, Glenn CC, Pike BR,Wang KK,Hayes
RL (2002) Up-regulation of tissue-type transglutaminase after trau-
matic brain injury. J Neurochem 80:579–588.
Tolentino PJ, Waghray A,Wang KK, Hayes RL (2004) Increased expression
of tissue-type transglutaminase following middle cerebral artery occlu-
sion in rats. J Neurochem 89:1301–1307.
Wang X, Wang H, Xu L, Rozanski DJ, Sugawara T, Chan PH, Trzaskos JM,
Feuerstein GZ (2003) Significant neuroprotection against ischemic
brain injury by inhibition of the MEK1 protein kinase in mice: explora-
tion of potential mechanism associated with apoptosis. J Pharmacol Exp
Ther 304:172–178.
Zaman K, Ryu H, Hall D, O’Donovan K, Lin KI, Miller MP, Marquis JC,
Baraban JM, Semenza GL, Ratan RR (1999) Protection from oxidative
stress-induced apoptosis in cortical neuronal cultures by iron chelators is
associated with enhanced DNA binding of hypoxia-inducible factor-1
and ATF-1/CREB and increased expression of glycolytic enzymes,
p21(waf1/cip1), and erythropoietin. J Neurosci 19:9821–9830.
Basso et al. • Transglutaminase1, 2, and Neuronal Oxidative Stress J. Neurosci., May 9, 2012 • 32(19):6561–6569 • 6569
